Rhenman & Partners Asset Management AB
Latest statistics and disclosures from Rhenman & Partners Asset Management AB's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ABBV, BMRN, HZNP, MDT, UNH, and represent 17.66% of Rhenman & Partners Asset Management AB's stock portfolio.
- Added to shares of these 10 stocks: ABBV (+$24M), TDOC (+$23M), JNJ (+$18M), MRK (+$15M), RPRX (+$13M), CVS (+$12M), MDT (+$12M), SGEN (+$11M), REGN (+$8.5M), JAZZ (+$8.3M).
- Started 15 new stock positions in AMWL, OSH, FPRX, STXS, GDRX, ANNX, DCPH, JNJ, CTIC, RPRX. TDOC, EPIX, PHAT, AUPH, SGEN.
- Reduced shares in these 10 stocks: NVCR (-$50M), Myokardia (-$26M), Livongo Health (-$23M), BMRN (-$21M), Immunomedics (-$19M), ALXN (-$16M), Seattle Genetics (-$14M), ARNA (-$11M), GH (-$9.0M), HZNP (-$6.9M).
- Sold out of its positions in ABEO, AMRN, BLUE, CLLS, CVX, F, Immunomedics, INCY, Livongo Health, Myokardia. QCOM, Seattle Genetics, RARE, QURE.
- Rhenman & Partners Asset Management AB was a net seller of stock by $-34M.
- Rhenman & Partners Asset Management AB has $1.2B in assets under management (AUM), dropping by 8.98%.
Tip: Access up to 7 years of quarterly data
Positions held by Rhenman & Partners Asset Management AB consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Rhenman & Partners Asset Management AB
Companies in the Rhenman & Partners Asset Management AB portfolio as of the December 2020 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Abbvie (ABBV) | 4.4 | $54M | +78% | 500k | 107.15 | |
| BioMarin Pharmaceutical (BMRN) | 3.6 | $45M | -31% | 510k | 87.69 | |
| Horizon Therapeutics Pub SHS (HZNP) | 3.6 | $44M | -13% | 600k | 73.15 | |
| Medtronic SHS (MDT) | 3.1 | $38M | +44% | 320k | 117.14 | |
| UnitedHealth (UNH) | 3.0 | $37M | -4% | 105k | 350.68 | |
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 3.0 | $36M | +29% | 220k | 165.05 | |
| Eli Lilly & Co. (LLY) | 2.5 | $30M | +9% | 180k | 168.84 | |
| Cigna Corp (CI) | 2.4 | $29M | -6% | 140k | 208.18 | |
| CVS Caremark Corporation (CVS) | 2.3 | $29M | +75% | 420k | 68.30 | |
| Merck & Co (MRK) | 2.3 | $28M | +115% | 344k | 81.80 | |
| Vertex Pharmaceuticals Incorporated (VRTX) | 2.2 | $27M | +4% | 115k | 236.34 | |
| Anthem (ANTM) | 2.1 | $26M | -11% | 80k | 321.09 | |
| Humana (HUM) | 1.9 | $24M | -3% | 58k | 410.28 | |
| Teladoc (TDOC) | 1.9 | $23M | NEW | 115k | 199.96 | |
Setup an alertRhenman & Partners Asset Management AB will file the next quarterly 13-HR in about 2 months. Would you like to be notified? |
||||||
| Axonics Modulation Technolog (AXNX) | 1.9 | $23M | 460k | 49.92 | ||
| Nektar Therapeutics (NKTR) | 1.9 | $23M | +35% | 1.4M | 17.00 | |
| Gilead Sciences (GILD) | 1.8 | $22M | +32% | 385k | 58.26 | |
| Mirati Therapeutics (MRTX) | 1.8 | $22M | -12% | 100k | 219.64 | |
| Guardant Health (GH) | 1.8 | $22M | -29% | 170k | 128.88 | |
| Bristol Myers Squibb (BMY) | 1.7 | $21M | +17% | 340k | 62.03 | |
| Novocure Ord Shs (NVCR) | 1.7 | $21M | -70% | 120k | 173.04 | |
| Acceleron Pharma (XLRN) | 1.7 | $21M | +10% | 160k | 127.94 | |
| Abiomed (ABMD) | 1.7 | $20M | -10% | 63k | 324.21 | |
| Biohaven Pharmaceutical Holding (BHVN) | 1.6 | $20M | -24% | 235k | 85.71 | |
| Cooper Cos Com New (COO) | 1.6 | $20M | -8% | 55k | 363.33 | |
| Regeneron Pharmaceuticals (REGN) | 1.6 | $19M | +77% | 40k | 483.10 | |
| Boston Scientific Corporation (BSX) | 1.6 | $19M | +17% | 530k | 35.95 | |
| Alexion Pharmaceuticals (ALXN) | 1.5 | $19M | -45% | 120k | 156.24 | |
| Johnson & Johnson (JNJ) | 1.5 | $18M | NEW | 115k | 157.38 | |
| Centene Corporation (CNC) | 1.4 | $17M | -5% | 285k | 60.03 | |
| Baxter International (BAX) | 1.3 | $16M | +32% | 205k | 80.24 | |
| Abbott Laboratories (ABT) | 1.3 | $16M | -26% | 150k | 109.49 | |
| Intra Cellular Therapies (ITCI) | 1.3 | $16M | +5% | 500k | 31.80 | |
| Apellis Pharmaceuticals (APLS) | 1.3 | $15M | +20% | 270k | 57.20 | |
| Esperion Therapeutics (ESPR) | 1.3 | $15M | +30% | 592k | 26.00 | |
| Iovance Biotherapeutics (IOVA) | 1.2 | $15M | -5% | 320k | 46.40 | |
| Alnylam Pharmaceuticals (ALNY) | 1.2 | $15M | +11% | 112k | 129.97 | |
| Neurocrine Biosciences (NBIX) | 1.2 | $14M | +100% | 150k | 95.85 | |
| Macrogenics (MGNX) | 1.2 | $14M | 625k | 22.86 | ||
| Sangamo Biosciences (SGMO) | 1.0 | $13M | +21% | 822k | 15.61 | |
| Thermo Fisher Scientific (TMO) | 1.0 | $13M | -8% | 28k | 465.79 | |
| Livanova SHS (LIVN) | 1.0 | $13M | -9% | 190k | 66.21 | |
| Royalty Pharma Shs Class A (RPRX) | 1.0 | $13M | NEW | 250k | 50.05 | |
| Hca Holdings (HCA) | 1.0 | $12M | 75k | 164.47 | ||
| Aerie Pharmaceuticals (AERI) | 0.9 | $12M | 850k | 13.51 | ||
| Edwards Lifesciences (EW) | 0.9 | $11M | +4% | 125k | 91.23 | |
| Seagen (SGEN) | 0.9 | $11M | NEW | 65k | 175.14 | |
| Xencor (XNCR) | 0.9 | $11M | 259k | 43.63 | ||
| Becton, Dickinson and (BDX) | 0.9 | $11M | +28% | 45k | 250.22 | |
| Zimmer Holdings (ZBH) | 0.8 | $10M | -20% | 65k | 154.09 | |
| EXACT Sciences Corporation (EXAS) | 0.8 | $9.9M | -6% | 75k | 132.49 | |
| Biogen Idec (BIIB) | 0.8 | $9.8M | +21% | 40k | 244.85 | |
| Glaukos (GKOS) | 0.8 | $9.4M | -10% | 125k | 75.26 | |
| Radius Health Com New (RDUS) | 0.7 | $8.6M | +45% | 482k | 17.86 | |
| Silk Road Medical Inc Common (SILK) | 0.6 | $7.9M | -10% | 125k | 62.98 | |
| Meiragtx Holdings (MGTX) | 0.6 | $6.8M | +20% | 450k | 15.14 | |
| Adverum Biotechnologies (ADVM) | 0.6 | $6.8M | 625k | 10.84 | ||
| Accolade (ACCD) | 0.5 | $6.5M | 150k | 43.50 | ||
| Revance Therapeutics (RVNC) | 0.5 | $6.2M | 220k | 28.34 | ||
| Shockwave Med (SWAV) | 0.5 | $6.2M | 60k | 103.72 | ||
| Rigel Pharmaceuticals Com New (RIGL) | 0.5 | $6.1M | 1.7M | 3.50 | ||
| Phathom Pharmaceuticals (PHAT) | 0.5 | $5.8M | NEW | 175k | 33.22 | |
| Intuitive Surgical Com New (ISRG) | 0.5 | $5.7M | -41% | 7.0k | 818.14 | |
| Agios Pharmaceuticals (AGIO) | 0.5 | $5.6M | +44% | 130k | 43.33 | |
| Myovant Sciences (MYOV) | 0.5 | $5.5M | -47% | 200k | 27.62 | |
| Fibrogen (FGEN) | 0.4 | $5.4M | 145k | 37.09 | ||
| Arena Pharmaceuticals Com New (ARNA) | 0.4 | $5.4M | -66% | 70k | 76.83 | |
| G1 Therapeutics (GTHX) | 0.4 | $4.3M | +26% | 240k | 17.99 | |
| Five Prime Therapeutics (FPRX) | 0.3 | $4.3M | NEW | 250k | 17.01 | |
| Alkermes SHS (ALKS) | 0.3 | $4.2M | -32% | 209k | 19.95 | |
| Dynavax Technologies Corp Com New (DVAX) | 0.3 | $4.1M | 926k | 4.45 | ||
| Oak Street Health (OSH) | 0.3 | $3.7M | NEW | 60k | 61.17 | |
| Deciphera Pharmaceuticals (DCPH) | 0.3 | $3.4M | NEW | 60k | 57.07 | |
| Annexon (ANNX) | 0.3 | $3.3M | NEW | 130k | 25.03 | |
| Viewray (VRAY) | 0.2 | $3.0M | 775k | 3.82 | ||
| Epizyme (EPZM) | 0.2 | $2.9M | 265k | 10.86 | ||
| Stereotaxis Com New (STXS) | 0.2 | $2.9M | NEW | 564k | 5.09 | |
| Essa Pharma Com New (EPIX) | 0.2 | $1.9M | NEW | 157k | 11.93 | |
| Aurinia Pharmaceuticals (AUPH) | 0.1 | $1.7M | NEW | 125k | 13.83 | |
| American Well Corp Cl A (AMWL) | 0.1 | $1.5M | NEW | 60k | 25.33 | |
| Goodrx Hldgs Com Cl A (GDRX) | 0.1 | $1.4M | NEW | 35k | 40.34 | |
| Cti Biopharma (CTIC) | 0.1 | $966k | NEW | 300k | 3.22 | |
| Pieris Pharmaceuticals (PIRS) | 0.1 | $750k | 300k | 2.50 | ||
Past Filings by Rhenman & Partners Asset Management AB
SEC 13F filings are viewable for Rhenman & Partners Asset Management AB going back to 2013
- Rhenman & Partners Asset Management AB 2020 Q4 filed Jan. 19, 2021
- Rhenman & Partners Asset Management AB 2020 Q3 filed Oct. 13, 2020
- Rhenman & Partners Asset Management AB 2020 Q2 filed July 16, 2020
- Rhenman & Partners Asset Management AB 2020 Q1 filed April 16, 2020
- Rhenman & Partners Asset Management AB 2019 Q4 filed Jan. 17, 2020
- Rhenman & Partners Asset Management AB 2019 Q3 filed Oct. 16, 2019
- Rhenman & Partners Asset Management AB 2019 Q2 filed July 22, 2019
- Rhenman & Partners Asset Management AB 2019 Q1 filed April 11, 2019
- Rhenman & Partners Asset Management AB 2018 Q4 filed Feb. 5, 2019
- Rhenman & Partners Asset Management AB 2018 Q3 filed Oct. 3, 2018
- Rhenman & Partners Asset Management AB 2018 Q2 filed July 20, 2018
- Rhenman & Partners Asset Management AB 2018 Q1 filed April 11, 2018
- Rhenman & Partners Asset Management AB 2017 Q4 filed Jan. 19, 2018
- Rhenman & Partners Asset Management AB 2017 Q3 filed Oct. 13, 2017
- Rhenman & Partners Asset Management AB 2017 Q2 filed July 11, 2017
- Rhenman & Partners Asset Management AB 2017 Q1 filed April 19, 2017